

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal646jxs

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	SEP 09	CA/CAPLUS records now contain indexing from 1907 to the present
NEWS	4	AUG 05	New pricing for EUROPATFULL and PCTFULL effective August 1, 2003
NEWS	5	AUG 13	Field Availability (/FA) field enhanced in BEILSTEIN
NEWS	6	AUG 18	Data available for download as a PDF in RDISCLOSURE
NEWS	7	AUG 18	Simultaneous left and right truncation added to PASCAL
NEWS	8	AUG 18	FROSTI and KOSMET enhanced with Simultaneous Left and Right Truncation
NEWS	9	AUG 18	Simultaneous left and right truncation added to ANABSTR
NEWS	10	SEP 22	DIPPR file reloaded
NEWS	11	DEC 08	INPADOC: Legal Status data reloaded
NEWS	12	SEP 29	DISSABS now available on STN
NEWS	13	OCT 10	PCTFULL: Two new display fields added
NEWS	14	OCT 21	BIOSIS file reloaded and enhanced
NEWS	15	OCT 28	BIOSIS file segment of TOXCENTER reloaded and enhanced
NEWS	16	NOV 24	MSDS-CCOHS file reloaded
NEWS	17	DEC 08	CABA reloaded with left truncation
NEWS	18	DEC 08	IMS file names changed
NEWS	19	DEC 09	Experimental property data collected by CAS now available in REGISTRY
NEWS	20	DEC 09	STN Entry Date available for display in REGISTRY and CA/CAPLUS
NEWS	21	DEC 17	DGENE: Two new display fields added
NEWS	22	DEC 18	BIOTECHNO no longer updated
NEWS	23	DEC 19	CROPU no longer updated; subscriber discount no longer available
NEWS	24	DEC 22	Additional INPI reactions and pre-1907 documents added to CAS databases
NEWS	25	DEC 22	IFIPAT/IFIUDB/IFICDB reloaded with new data and search fields
NEWS	26	DEC 22	ABI-INFORM now available on STN
NEWS EXPRESS			NOVEMBER 14 CURRENT WINDOWS VERSION IS V6.01c, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 23 SEPTEMBER 2003
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 18:04:54 ON 22 DEC 2003

=> file medline caplus biosis embase cancerlit

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'MEDLINE' ENTERED AT 18:05:19 ON 22 DEC 2003

FILE 'CAPLUS' ENTERED AT 18:05:19 ON 22 DEC 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 18:05:19 ON 22 DEC 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'EMBASE' ENTERED AT 18:05:19 ON 22 DEC 2003

COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.

FILE 'CANCERLIT' ENTERED AT 18:05:19 ON 22 DEC 2003

=> s tn timer (w)necrosis (w) factor

L1 333675 TNF OR TUMOR (W) NECROSIS (W) FACTOR

=> s (tn timer (w)necrosis (w) factor) (w) antibodies

L2 918 (TNF OR TUMOR (W) NECROSIS (W) FACTOR) (W) ANTIBODIES

=> l2 (S) (MIP-1b or RANTES)

L2 IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter

"HELP COMMANDS" at an arrow prompt (=>).

=> s l2 (S) (MIP-1b or RANTES)

L3 2 L2 (S) (MIP-1B OR RANTES)

=> d l3 1- ibib,abs

YOU HAVE REQUESTED DATA FROM 2 ANSWERS - CONTINUE? Y/(N):y

L3 ANSWER 1 OF 2 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

ACCESSION NUMBER: 96342263 EMBASE

DOCUMENT NUMBER: 1996342263

TITLE: Tumor necrosis factor (TNF) in inflammatory bowel disease:  
Gene polymorphisms, animal models, and potential for  
anti-TNF therapy.

AUTHOR: Stokkers P.C.F.; Camoglio L.; Van Deventer S.J.H.

CORPORATE SOURCE: Lab. for Experimental Internal Med., Meibergdreef 9, 1105 AZ  
Amsterdam, Netherlands

SOURCE: Journal of Inflammation, (1995) 47/1-2 (97-103).

ISSN: 1078-7852 CODEN: JOINFB

COUNTRY: United States

DOCUMENT TYPE: Journal; Conference Article

FILE SEGMENT: 026 Immunology, Serology and Transplantation

LANGUAGE: English

SUMMARY LANGUAGE: English

AB The inflammatory bowel diseases frequently require surgery because of  
intestinal complications. Animal models of inflammatory bowel disease, in  
particular those that histopathologically resemble Crohn's disease, are  
characterized by increased mucosal TNF production, and anti-TNF

**antibodies** have shown efficacy in decreasing disease activity. These data have provided a rationale for immunotherapy of Crohn's disease. Administration of anti-**TNF antibodies** to patients with Crohn's disease not responding to standard immunosuppressive treatment rapidly induced complete remissions, and healing of intestinal ulceration. A rapid reduction of circulating IL-6, CPR, and sPLA2 levels was observed in all patients, as well as a reduction of mucosal cells expressing **RANTES** and MIP-1. Short-term treatment with anti-**TNF antibodies** was not associated with significant toxicity, but results from long-term administration are still lacking. These data indicate that TNF is a pivotal and central inflammatory mediator in this disease. Further characterization of the precise mechanism of action of anti-TNF antibody therapy may further unravel the cause of immune dysregulation in Crohn's disease.

L3 ANSWER 2 OF 2 CANCERLIT on STN  
 ACCESSION NUMBER: 97071010 CANCERLIT  
 DOCUMENT NUMBER: 97071010 PubMed ID: 8913936  
 TITLE: Tumor necrosis factor (TNF) in inflammatory bowel disease: gene polymorphisms, animal models, and potential for anti-TNF therapy.  
 AUTHOR: Stokkers P C; Camoglio L; van Deventer S J  
 CORPORATE SOURCE: Laboratory for Experimental Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands.  
 SOURCE: JOURNAL OF INFLAMMATION, (1995-96) 47 (1-2) 97-103. Ref: 54  
 Journal code: 9511967. ISSN: 1078-7852.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 General Review; (REVIEW)  
 (REVIEW, TUTORIAL)  
 LANGUAGE: English  
 FILE SEGMENT: MEDLINE; Priority Journals  
 OTHER SOURCE: MEDLINE 97071010  
 ENTRY MONTH: 199702  
 ENTRY DATE: Entered STN: 19970305  
 Last Updated on STN: 19970305

AB The inflammatory bowel diseases frequently require surgery because of intestinal complications. Animal models of inflammatory bowel disease, in particular those that histopathologically resemble Crohn's disease, are characterized by increased mucosal TNF production, and anti-**TNF antibodies** have shown efficacy in decreasing disease activity. These data have provided a rationale for immunotherapy of Crohn's disease. Administration of anti-**TNF antibodies** to patients with Crohn's disease not responding to standard immunosuppressive treatment rapidly induced complete remissions, and healing of intestinal ulceration. A rapid reduction of circulating IL-6, CPR, and sPLA2 levels was observed in all patients, as well as a reduction of mucosal cells expressing **RANTES** and MIP-1. Short-term treatment with anti-**TNF antibodies** was not associated with significant toxicity, but results from long-term administration are still lacking. These data indicate that TNF is a pivotal and central inflammatory mediator in this disease. Further characterization of the precise mechanism of action of anti-TNF antibody therapy may further unravel the cause of immune dysregulation in Crohn's disease.

=> d his

(FILE 'HOME' ENTERED AT 18:04:54 ON 22 DEC 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, CANCERLIT' ENTERED AT 18:05:19 ON 22 DEC 2003

L1 333675 S TNF OR TUMOR (W) NECROSIS (W) FACTOR  
 L2 918 S (TNF OR TUMOR (W) NECROSIS (W) FACTOR) (W) ANTIBODIES

L3 2 S L2 (S) (MIP-1B OR RANTES)

=> s l1 S (fusion or conjugate) s chemokine?

MISSING OPERATOR L1 S

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s s l1 S (fusion or conjugate)

MISSING OPERATOR S L1

The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l1 (s) (fusion? or conjugate?)

L4 3699 L1 (S) (FUSION? OR CONJUGATE?)

=> s l4 (s) chemokine?

L5 42 L4 (S) CHEMOKINE?

=> s l5 (s) antibodies

L6 5 L5 (S) ANTIBODIES

=> duplicate remove l6

DUPLICATE PREFERENCE IS 'EMBASE, CANCERLIT'

KEEP DUPLICATES FROM MORE THAN ONE FILE? Y/(N):n

PROCESSING COMPLETED FOR L6

L7 3 DUPLICATE REMOVE L6 (2 DUPLICATES REMOVED)

=> d l7 1-

YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 3 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN

AN 2003161017 EMBASE

TI Cytokine, chemokine, and costimulatory molecule modulation to enhance efficacy of HIV vaccines.

AU Ahlers J.D.; Belyakov I.M.; Berzofsky J.A.

CS J.A. Berzofsky, Molec. Immunogen./Vaccine Res. Sec., Metabolism Branch, National Cancer Institute, Building 10, Bethesda, MD 20892-1578, United States. jahlers@niaid.nih.gov

SO Current Molecular Medicine, (2003) 3/3 (285-301).

Refs: 206

ISSN: 1566-5240 CODEN: CMMUBP

CY Netherlands

DT Journal; General Review

FS 004 Microbiology

026 Immunology, Serology and Transplantation

030 Pharmacology

037 Drug Literature Index

039 Pharmacy

LA English

SL English

L7 ANSWER 2 OF 3 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
on STN DUPLICATE 1

AN 2001154626 EMBASE

TI Anti-TNF.alpha. therapy of rheumatoid arthritis: What have we learned?.

AU Feldmann M.; Maini R.N.

CS M. Feldmann, Kennedy Inst. of Rheumatology Div., Imperial College School of Medicine, 1 Aspenlea Road, London W6 8LH, United Kingdom. m.feldmann@ic.ac.uk

SO Annual Review of Immunology, (2001) 19/- (163-196).

Refs: 160

ISSN: 0732-0582 CODEN: ARIMDU

CY United States

DT Journal; General Review

FS 026 Immunology, Serology and Transplantation  
 031 Arthritis and Rheumatism  
 037 Drug Literature Index  
 LA English  
 SL English  
  
 L7 ANSWER 3 OF 3 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.  
 on STN DUPLICATE 2  
 AN 1998362492 EMBASE  
 TI Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture,  
 firm adhesion, and activation under physiologic flow.  
 AU Fong A.M.; Robinson L.A.; Steeber D.A.; Tedder T.F.; Yoshie O.; Imai T.;  
 Patel D.D.  
 CS D.D. Patel, Box 3258, 222 CARL Bldg., Duke University Medical Center,  
 Durham, NC 27710, United States. patel003@mc.duke.edu  
 SO Journal of Experimental Medicine, (19 Oct 1998) 188/8 (1413-1419).  
 Refs: 28  
 ISSN: 0022-1007 CODEN: JEMEA  
 CY United States  
 DT Journal; Article  
 FS 025 Hematology  
 029 Clinical Biochemistry  
 LA English  
 SL English

=> d his

(FILE 'HOME' ENTERED AT 18:04:54 ON 22 DEC 2003)

FILE 'MEDLINE, CAPLUS, BIOSIS, EMBASE, CANCERLIT' ENTERED AT 18:05:19 ON  
22 DEC 2003

L1 333675 S TNF OR TUMOR (W) NECROSIS (W) FACTOR  
 L2 918 S (TNF OR TUMOR (W) NECROSIS (W) FACTOR) (W) ANTIBODIES  
 L3 2 S L2 (S) (MIP-1B OR RANTES)  
 L4 3699 S L1 (S) (FUSION? OR CONJUGATE?)  
 L5 42 S L4 (S) CHEMOKINE?  
 L6 5 S L5 (S) ANTIBODIES  
 L7 3 DUPLICATE REMOVE L6 (2 DUPLICATES REMOVED)

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	50.13	50.34

STN INTERNATIONAL LOGOFF AT 18:16:58 ON 22 DEC 2003